Bai-wei Gu has more than 20 years of experience in molecular virology, cell line development, and gene/cell therapy process development, both in academic and industry environments. He currently works at WuXi AppTec as a head of cell line development. His group is responsible for developing high-yield proprietary cell lines for viral vector production in the gene and cell therapy segment. Bai-wei has authored more than 50 book chapters and peer-reviewed journal publications.

Juan Lagos is an associate director of upstream process development in the process and technology development department at WuXi Advanced Therapies. Juan has 18 years of industry experience in cell culture and upstream process development from cell line development to commercialization. That experience includes work with clone selection; media development; fed-batch and perfusion process optimization; scale-up; and characterization and harvest of IgG, IgM, fusion proteins, and viral vectors. Prior to WuXi, Juan worked at Pathon, a subsidiary of Thermo Fisher BMS, and Schering Plough (Merck). Juan is presently working towards his Ph.D. in Biochemical Engineering at the Rutgers University College of Engineering. He holds a B.S. in both biochemical engineering and computer science from Rutgers University.

Matthew Weaver has more than 10 years of experience in analytics and up- and downstream process development for viral vectors and vaccines. He currently works at WuXi AppTec as head of downstream process development for cell therapies and viral vectors.